As seen in Study 1, several features declined with NASH, including the expression of genes involved in triglyceride catabolism (ATGL, TGH/Ces3), fatty acid elongation (Elovl5) and hepatic ω3 and ω6 PUFA content. The gene discussed is PNPLA2; the disease is metabolic dysfunction-associated steatohepatitis.